K O 7 E06
51008) Summary
Submitter: Cynosure, Inc.
5 Carlisle Road
Westford, MA 01886 JAN 8 0 2007

Contact: George Cho
Senior Vice President of Medical Technology

Date Summary Prepared: January 4, 2007

Device Trade Name: Cynosure YAG MIR II Laser

Common Name: Medical Laser System

Classification Name: Instrument, surgical, powered, laser
79-GEX
21 CFR 878.4810

Equivalent Device: Cynosure YAG Family laser, Cynosure YAG MIR Family laser

Device Description: The Cynosure YAG MIR II laser is a Nd:YAG laser, having a
ND:YAG crystal rod as a lasing medium.

Laser activation is by footswitch or finger switch. Overall weight of
the laser is 285lbs, and the size is 41”x18”"x32” (HxWxD).
Electrical requirement is 220 VAC, 30A, 50-60 Hz, single phase.

Intended Use: The Cynosure YAG MIR II Laser is indicated for the treatment of
vascular and pigmented lesions and wrinkles.

Comparison: The Cynosure YAG MIR II Laser has the same indications for use, the
same principle of operation, and same wavelengths and pulse energy
range as the predicate device(s).

Nonclinical Performance Data: none

Clinical Performance Data: none

Conclusion: The CynosureYAG MIR II Laser is a safe and effective device for the
indications specified.

Additional Information: none

2 ¢ DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
“hava Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850
Cynosure Incorporated
% Mr. George Cho JAN 3 0 2007
Senior Vice President .
5 Carlisle Road
Westford, Massachusetts 01886
Re: K070063
Trade/Device Name: CynosureYAG MIR II Laser
Regulation Number: 21 CFR 878.4810,
Regulation Name: Laser surgical instrument for use in general and plastic surgery and in
dermatology. :
Regulatory Class: Class H
Product Code: GEX
Dated: January 4, 2007
Received: January 8, 2007
Dear Mr. Cho:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 — Mr. George Cho
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (240) 276-0115 Also, please note the regulation entitled,
"Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(240) 276-3150 or at its Internet-address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

\ Ww
{*
Mark N. Melkerson
. Director
Division of General, Restorative
and Neurological Devices
: Office of Device Evaluation

Center for Devices and

Radiological Health
Enclosure .

510(k) Number (if known): KK OY6063
Device Name: _ Cynosure YAG MIR TI Laser .
Indications For Use:
1064nm: The Cynosure YAG MIR II laser is intended for the coagulation and hemostasis of benign
vascular lesions, such as , but not limited to, port wine stains, hemangiomas, warts, telangiectasia,
rosacea, venus lake, leg veins, spider veins and poikiloderma of civatte; and treatment of benign
cutaneous lesions such as warts, scars, striae and psoriasis. The laser is also intended for the treatment
of benign pigmented lesions such as, but not limited to, lentigos (age spots), solar lentigos (sun spots),
Café au lait macules, seborrheic keratoses, nevi, chloasma, verrucea, skin tags, keratoses, tattoos
(significant reduction in the intensity of black and/or blue/black tattoos) and plaques.
The laser is also indicated for the treatment of wrinkles such as, but not limited to, periocular and
perioral wrinkles.
1320nm: The Cynosure YAG MIR TI laser is indicated for use in general surgery and dermatology for
the incision, excision, ablation, vaporization, coagulation and hemostasis of soft tissue. It is also
indicated for the treatment of periorbital and perioral wrinkles. It is also indicated for the treatment of
fine lines and wrinkles.
1440nm: The Cynosure YAG MIR I laser is indicated for use in general surgery and dermatology for
the incision, excision, ablation, vaporization, coagulation and hemostasis of soft tissue. It is also
indicated for the treatment of periorbital and perioral wrinkles and pigmented lesions.
Prescriptive Use x OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (Part 21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
ul)
(Division ‘Sign-Off)
Division of General, Restorative,
and Neurolo 4! Devices
£404) Nur, LM 062

